ziprasidone superior to haloperidol in schizophrenia

Inpharma 1351 - 17 Aug 2002 Ziprasidone superior to haloperidol in schizophrenia Compared with haloperidol, ziprasidone is as effective and has a better tolerability profile, in the treatment of patients with stable chronic schizophrenia, according to a multinational group of researchers. * The study involved 301 outpatients aged 18–64 years with stable chronic or subchronic schizophrenia requiring antipsychotic maintenance treatment. The patients were randomised to receive ziprasidone 80–160 mg/day (n = 148) or haloperidol 5–15 mg/day, for 28 weeks. There were no significant between-group differences in treatment-induced changes in PANSS, BPRSd, MADRS, CGI-S, or QLS scores. ** There was also no significant difference between the treatment groups in the proportion of patients in remission (a PANSS score of < 60) at the end of treatment. However, there were significantly more negative symptom responders in the ziprasidone group, compared with the haloperidol group (48% vs 33% of patients). † The rates of completion and discontinuation of treatment due to lack of efficacy were similar between the two groups. However, the rate of discontinuation due to treatment-related adverse events was twice as high in the haloperidol group, compared with the ziprasidone group (16% vs 8%). * Two of the researchers were associated with Pfizer, which provided funding for the study. ** PANSS = Positive and Negative Syndrome Scale; BPRSd = Brief Psychiatric Rating Scale derived from the PANSS; MADRS = Montgomery- ˚ Asberg Depression Rating Scale; CGI-S = Clinical Global Impressions-Severity of Illness scale; QLS = Quality of Life Scale † A negative symptom responder was defined as a patient with a ≥ 20% decrease from baseline in the PANSS negative subscale score. Hirsch SR, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Journal of Clinical Psychiatry 63: 516-523, Jun 2002 800913854 1 Inpharma 17 Aug 2002 No. 1351 1173-8324/10/1351-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 11-Dec-2016

213 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

Inpharma 1351 - 17 Aug 2002

Ziprasidone superior to haloperidolin schizophrenia

Compared with haloperidol, ziprasidone is aseffective and has a better tolerability profile, in thetreatment of patients with stable chronic schizophrenia,according to a multinational group of researchers.*

The study involved 301 outpatients aged 18–64 yearswith stable chronic or subchronic schizophreniarequiring antipsychotic maintenance treatment. Thepatients were randomised to receive ziprasidone80–160 mg/day (n = 148) or haloperidol 5–15 mg/day,for 28 weeks.

There were no significant between-group differencesin treatment-induced changes in PANSS, BPRSd,MADRS, CGI-S, or QLS scores.** There was also nosignificant difference between the treatment groups inthe proportion of patients in remission (a PANSS scoreof < 60) at the end of treatment. However, there weresignificantly more negative symptom responders in theziprasidone group, compared with the haloperidolgroup (48% vs 33% of patients).†

The rates of completion and discontinuation oftreatment due to lack of efficacy were similar betweenthe two groups. However, the rate of discontinuationdue to treatment-related adverse events was twice ashigh in the haloperidol group, compared with theziprasidone group (16% vs 8%).* Two of the researchers were associated with Pfizer, which providedfunding for the study.** PANSS = Positive and Negative Syndrome Scale; BPRSd = BriefPsychiatric Rating Scale derived from the PANSS; MADRS =Montgomery-Asberg Depression Rating Scale; CGI-S = Clinical GlobalImpressions-Severity of Illness scale; QLS = Quality of Life Scale† A negative symptom responder was defined as a patient with a ≥ 20%decrease from baseline in the PANSS negative subscale score.

Hirsch SR, et al. A 28-week comparison of ziprasidone and haloperidol inoutpatients with stable schizophrenia. Journal of Clinical Psychiatry 63: 516-523,Jun 2002 800913854

Treatment & Referral Guidesadag.org/images/brochures/Schizophrenia Brochure.pdf · SCHIZOPHRENIA Treatment & Referral Guide How to recognise Schizophrenia ... !Catatonic schizophrenia!Schizo-affective

Ziprasidone Capsules Type of Posting Revision Bulletin ...€¦ · 27/9/2019 · [email protected]). CC CC rev . Ziprasidone Capsules DEFINITION Ziprasidone Capsules contain an

Haloperidol Decanoate

ACUTE PSYCHOSIS MANAGEMENTReduction in PANSS-EC and ACES scores Olanzapine > Levomepromazine > haloperidol EPS Symptoms (Dyskinesia, dystonia) Haloperidol > olanzapine/levomepromazine

1 Schizophrenia Module 39. 2 3 Psychological Disorders Schizophrenia overview Symptoms of Schizophrenia Onset and Development of Schizophrenia

Haloperidol - cdn.ymaws.com · • 1969 Haloperidol patent granted in the United States • 1976 Solomon Snyder confirms that Haloperidol is a dopamine receptor antagonist • 1982

Efﬁcacy of ziprasidone in controlling agitation during ...downloads.hindawi.com/journals/bn/2007/529076.pdf · Behavioural Neurology 18 (2007) 7–11 7 IOS Press Efﬁcacy of ziprasidone

Current Biological Treatments of Schizophrenia...Adapted from Lieberman J, et al., APA Annual Meeting, May 2001 1900 '40s Reserpine Chlorpromazine Haloperidol Fluphenzaine Trifluperazine

Ziprasidone, haloperidol and clonazepam intramuscular … · comparing ziprasidone with haloperidol, and four studies comparing haloperidol with clonazepam. The results showed that

ibatiba.es.gov.br · Espironolactona Fenitoína Fenobarbital Fenobarbital Finasterida Fluconazol Fluoxetina Furosemida Glibenclamida Glicazida Glicazida Haloperidol Haloperidol Hidroclorotiazida

HIGHLIGHTS OF PRESCRIBING INFORMATION 3...Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic

Haloperidol ameliorates androgen-induced behavioral deficits in … · RESEARCH Haloperidol ameliorates androgen-induced behavioral deficits in developing male rats Chunxiao Qi1 ,